Through a new co-marketing partnership, liquid biopsy company ANGLE is set to develop its molecular testing solutions by integrating ANGLE’s cell separation technology, Parsortix, which harvests circulating tumour cells with its liquid biopsy solution portfolio.
The company’s technology is the subject of granted patents globally, with FDA authorisation in process for the US. The Parsotix technology will provide the ability to deliver personalised cancer care and improve patient outcomes.
With more than 500,000 customers in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research), Netherland’s based Qiagen’s liquid biopsy solution portfolio consists of dedicated NGS (next generation sequencing), PCR (polymerase chain reaction), single cell analysis products and bioinformatics capabilities.
However, its initial focus will be on prostate and breast cancer research applications.
The agreement entails both companies offering the other's products to its customer base and follows an intensive evaluation of Parsortix by Qiagen identifying the advantages of the system.
Many of Qiagen’s solutions have become fully integrated and are utilised in a multitude of diagnostic and research workflows, representing gold standards in terms of performance.
Such solutions allow liquid biopsies to be easier and less expensive to perform than tissue biopsies, enabling improved sensitivity, specificity and robustness which can be reliably repeated at regular intervals for monitoring of disease progression.
News of the partnership has seen an increase in shares.
Andrew Newland, ANGLE’s founder and chief executive, said: “We believe the ability to offer customers a combination of Parsortix with validated and reliable downstream analysis technologies from a world leader such as QIAGEN facilitates key aspects of the sales cycle and we look forward to working closely together.”
“Partnering is a core part of ANGLE's strategy to secure widespread adoption of Parsortix right across the market leveraging the customer base and distribution channels of established players."